<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02738203</url>
  </required_header>
  <id_info>
    <org_study_id>32825</org_study_id>
    <nct_id>NCT02738203</nct_id>
  </id_info>
  <brief_title>Self-Administered Lidocaine Gel for Pain Management With IUD Insertion</brief_title>
  <acronym>SALUD</acronym>
  <official_title>Self-Administered Lidocaine Gel for Pain Management With IUD Insertion: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      For intrauterine device (IUD) insertion, currently there are no standardized clinical
      guidelines for pain management. The investigators aim to explore whether adequate pain relief
      is possible through self-administered, non-invasive means alone. Reducing pain associated
      with IUD insertion may benefit patients and providers. When patients are comfortable during
      their procedure, it is likely the provider can more quickly and with fewer complications
      perform the insertion. The investigators propose to explore the effect of a locally applied
      vaginal lidocaine gel in place of the standard of care pain management, no intervention,
      prior to IUD insertions. This is a superiority, blinded, randomized controlled trial.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 1, 2016</start_date>
  <completion_date type="Actual">October 19, 2017</completion_date>
  <primary_completion_date type="Actual">October 19, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>(IUD Insertion): Pain Perceived by Visual Analogue Scale (0-100 mm) Immediately Following Procedure Completion</measure>
    <time_frame>0-3 minutes after procedure completed</time_frame>
    <description>Pain immediately after speculum removal as measured by a Visual Analog Scale (VAS). This scale is 0-100--on the scale &quot;0&quot; had &quot;no pain&quot; and &quot;100&quot; had &quot;worst pain imaginable&quot; as anchors. A higher score indicates higher pain.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anticipated Pain as Measured by a Visual Analog Scale</measure>
    <time_frame>30 Minutes prior to procedure</time_frame>
    <description>Pain as measured by a Visual Analog Scale (VAS). This scale is 0-100--on the scale &quot;0&quot; had &quot;no pain&quot; and &quot;100&quot; had &quot;worst pain imaginable&quot; as anchors. A higher score indicates higher pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline Pain as Measured by a Visual Analog Scale</measure>
    <time_frame>Immediately prior to procedure; upon arrival to procedure room</time_frame>
    <description>Pain as measured by a Visual Analog Scale (VAS). This scale is 0-100--on the scale &quot;0&quot; had &quot;no pain&quot; and &quot;100&quot; had &quot;worst pain imaginable&quot; as anchors. A higher score indicates higher pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain After Speculum Placement as Measured by a Visual Analog Scale</measure>
    <time_frame>Intraoperative</time_frame>
    <description>Pain as measured by a Visual Analog Scale (VAS). This scale is 0-100--on the scale &quot;0&quot; had &quot;no pain&quot; and &quot;100&quot; had &quot;worst pain imaginable&quot; as anchors. A higher score indicates higher pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain After Tenaculum Placement as Measured by a Visual Analog Scale</measure>
    <time_frame>Intraoperative</time_frame>
    <description>Pain as measured by a Visual Analog Scale (VAS). This scale is 0-100--on the scale &quot;0&quot; had &quot;no pain&quot; and &quot;100&quot; had &quot;worst pain imaginable&quot; as anchors. A higher score indicates higher pain.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">220</enrollment>
  <condition>IUD Insertion</condition>
  <arm_group>
    <arm_group_label>Experimental, IUD Insertion group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>If the subject is assigned to the experimental group (vaginal lidocaine jelly):
She will be given a pre-filled vaginal inserter with 10 ml of 2% lidocaine jelly) and will be asked to insert it vaginally 20-30 minutes prior to the start of her procedure. The subject will not know if she received the active drug or a placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control, IUD Insertion group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>If the subject is assigned to the control group (sterile, surgical lubricant jelly):
•She will be given a pre-filled vaginal inserter with 10 ml of surgical lubricant jelly and will be asked to insert it vaginally 20-30 minutes prior to the start of her procedure. The subject will not know if she received the active drug or a placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vaginal 2% Lidocaine</intervention_name>
    <description>Patient-administered vaginal Lidocaine jelly verse surgical lubricant jelly</description>
    <arm_group_label>Experimental, IUD Insertion group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Surgical Lubricant Jelly</intervention_name>
    <description>Patient-administered vaginal surgical lubricant jelly verse Lidocaine jelly</description>
    <arm_group_label>Control, IUD Insertion group</arm_group_label>
    <other_name>K-Y Jelly</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Elective IUD insertion (any type of IUD, copper or hormonal); at an out-patient setting at
        Stanford; English or Spanish speaking, and ability to give informed consent.

        Exclusion Criteria:

        Any pre-operative use of misoprostol; or use of PO pain control medication (i.e. ibuprofen
        or acetaminophen) prior to procedure. Allergy to study medications: lidocaine, or surgical
        lubricant jelly, known uterine anomaly; prior cervical surgery; and no prior use of
        tampons.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jennifer A Conti, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford Gynecology Clinic</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>April 4, 2016</study_first_submitted>
  <study_first_submitted_qc>April 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 14, 2016</study_first_posted>
  <results_first_submitted>August 7, 2018</results_first_submitted>
  <results_first_submitted_qc>September 17, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">September 18, 2018</results_first_posted>
  <last_update_submitted>June 4, 2019</last_update_submitted>
  <last_update_submitted_qc>June 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Jennifer Conti</investigator_full_name>
    <investigator_title>Clinical Instructor</investigator_title>
  </responsible_party>
  <keyword>Pain Management</keyword>
  <keyword>IUD insertion</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 1, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/03/NCT02738203/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Experimental, IUD Insertion Group</title>
          <description>If the subject is assigned to the experimental group (vaginal lidocaine jelly):
She will be given a pre-filled vaginal inserter with 10 ml of 2% lidocaine jelly) and will be asked to insert it vaginally 20-30 minutes prior to the start of her procedure. The subject will not know if she received the active drug or a placebo.
Vaginal 2% Lidocaine: Patient-administered vaginal Lidocaine jelly verse surgical lubricant jelly</description>
        </group>
        <group group_id="P2">
          <title>Control, IUD Insertion Group</title>
          <description>If the subject is assigned to the control group (sterile, surgical lubricant jelly):
•She will be given a pre-filled vaginal inserter with 10 ml of surgical lubricant jelly and will be asked to insert it vaginally 20-30 minutes prior to the start of her procedure. The subject will not know if she received the active drug or a placebo.
Surgical Lubricant Jelly: Patient-administered vaginal surgical lubricant jelly verse Lidocaine jelly</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="110"/>
                <participants group_id="P2" count="110"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="108"/>
                <participants group_id="P2" count="107"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Failed IUD Insertion</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Per protocol analysis</population>
      <group_list>
        <group group_id="B1">
          <title>Experimental, IUD Insertion Group</title>
          <description>If the subject is assigned to the experimental group (vaginal lidocaine jelly):
She will be given a pre-filled vaginal inserter with 10 ml of 2% lidocaine jelly) and will be asked to insert it vaginally 20-30 minutes prior to the start of her procedure. The subject will not know if she received the active drug or a placebo.
Vaginal 2% Lidocaine: Patient-administered vaginal Lidocaine jelly verse surgical lubricant jelly</description>
        </group>
        <group group_id="B2">
          <title>Control, IUD Insertion Group</title>
          <description>If the subject is assigned to the control group (sterile, surgical lubricant jelly):
•She will be given a pre-filled vaginal inserter with 10 ml of surgical lubricant jelly and will be asked to insert it vaginally 20-30 minutes prior to the start of her procedure. The subject will not know if she received the active drug or a placebo.
Surgical Lubricant Jelly: Patient-administered vaginal surgical lubricant jelly verse Lidocaine jelly</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="108"/>
            <count group_id="B2" value="107"/>
            <count group_id="B3" value="215"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.9" lower_limit="18" upper_limit="48"/>
                    <measurement group_id="B2" value="27" lower_limit="18" upper_limit="51"/>
                    <measurement group_id="B3" value="28" lower_limit="18" upper_limit="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="108"/>
                    <measurement group_id="B2" value="107"/>
                    <measurement group_id="B3" value="215"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="93"/>
                    <measurement group_id="B2" value="90"/>
                    <measurement group_id="B3" value="183"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="69"/>
                    <measurement group_id="B2" value="67"/>
                    <measurement group_id="B3" value="136"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="108"/>
                    <measurement group_id="B2" value="107"/>
                    <measurement group_id="B3" value="215"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Previous Intrauterine Device Insertion</title>
          <description>Participant had a previous intrauterine device insertion.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>(IUD Insertion): Pain Perceived by Visual Analogue Scale (0-100 mm) Immediately Following Procedure Completion</title>
        <description>Pain immediately after speculum removal as measured by a Visual Analog Scale (VAS). This scale is 0-100--on the scale &quot;0&quot; had &quot;no pain&quot; and &quot;100&quot; had &quot;worst pain imaginable&quot; as anchors. A higher score indicates higher pain.</description>
        <time_frame>0-3 minutes after procedure completed</time_frame>
        <population>Per protocol analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Experimental, IUD Insertion Group</title>
            <description>If the subject is assigned to the experimental group (vaginal lidocaine jelly):
She will be given a pre-filled vaginal inserter with 10 ml of 2% lidocaine jelly) and will be asked to insert it vaginally 20-30 minutes prior to the start of her procedure. The subject will not know if she received the active drug or a placebo.
Vaginal 2% Lidocaine: Patient-administered vaginal Lidocaine jelly verse surgical lubricant jelly</description>
          </group>
          <group group_id="O2">
            <title>Control, IUD Insertion Group</title>
            <description>If the subject is assigned to the control group (sterile, surgical lubricant jelly):
•She will be given a pre-filled vaginal inserter with 10 ml of surgical lubricant jelly and will be asked to insert it vaginally 20-30 minutes prior to the start of her procedure. The subject will not know if she received the active drug or a placebo.
Surgical Lubricant Jelly: Patient-administered vaginal surgical lubricant jelly verse Lidocaine jelly</description>
          </group>
        </group_list>
        <measure>
          <title>(IUD Insertion): Pain Perceived by Visual Analogue Scale (0-100 mm) Immediately Following Procedure Completion</title>
          <description>Pain immediately after speculum removal as measured by a Visual Analog Scale (VAS). This scale is 0-100--on the scale &quot;0&quot; had &quot;no pain&quot; and &quot;100&quot; had &quot;worst pain imaginable&quot; as anchors. A higher score indicates higher pain.</description>
          <population>Per protocol analysis</population>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65" lower_limit="1" upper_limit="99"/>
                    <measurement group_id="O2" value="59" lower_limit="5" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anticipated Pain as Measured by a Visual Analog Scale</title>
        <description>Pain as measured by a Visual Analog Scale (VAS). This scale is 0-100--on the scale &quot;0&quot; had &quot;no pain&quot; and &quot;100&quot; had &quot;worst pain imaginable&quot; as anchors. A higher score indicates higher pain.</description>
        <time_frame>30 Minutes prior to procedure</time_frame>
        <population>Per protocol analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Experimental, IUD Insertion Group</title>
            <description>If the subject is assigned to the experimental group (vaginal lidocaine jelly):
She will be given a pre-filled vaginal inserter with 10 ml of 2% lidocaine jelly) and will be asked to insert it vaginally 20-30 minutes prior to the start of her procedure. The subject will not know if she received the active drug or a placebo.
Vaginal 2% Lidocaine: Patient-administered vaginal Lidocaine jelly verse surgical lubricant jelly</description>
          </group>
          <group group_id="O2">
            <title>Control, IUD Insertion Group</title>
            <description>If the subject is assigned to the control group (sterile, surgical lubricant jelly):
•She will be given a pre-filled vaginal inserter with 10 ml of surgical lubricant jelly and will be asked to insert it vaginally 20-30 minutes prior to the start of her procedure. The subject will not know if she received the active drug or a placebo.
Surgical Lubricant Jelly: Patient-administered vaginal surgical lubricant jelly verse Lidocaine jelly</description>
          </group>
        </group_list>
        <measure>
          <title>Anticipated Pain as Measured by a Visual Analog Scale</title>
          <description>Pain as measured by a Visual Analog Scale (VAS). This scale is 0-100--on the scale &quot;0&quot; had &quot;no pain&quot; and &quot;100&quot; had &quot;worst pain imaginable&quot; as anchors. A higher score indicates higher pain.</description>
          <population>Per protocol analysis</population>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60" lower_limit="1" upper_limit="87"/>
                    <measurement group_id="O2" value="59" lower_limit="6" upper_limit="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Baseline Pain as Measured by a Visual Analog Scale</title>
        <description>Pain as measured by a Visual Analog Scale (VAS). This scale is 0-100--on the scale &quot;0&quot; had &quot;no pain&quot; and &quot;100&quot; had &quot;worst pain imaginable&quot; as anchors. A higher score indicates higher pain.</description>
        <time_frame>Immediately prior to procedure; upon arrival to procedure room</time_frame>
        <population>Per protocol analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Experimental, IUD Insertion Group</title>
            <description>If the subject is assigned to the experimental group (vaginal lidocaine jelly):
She will be given a pre-filled vaginal inserter with 10 ml of 2% lidocaine jelly) and will be asked to insert it vaginally 20-30 minutes prior to the start of her procedure. The subject will not know if she received the active drug or a placebo.
Vaginal 2% Lidocaine: Patient-administered vaginal Lidocaine jelly verse surgical lubricant jelly</description>
          </group>
          <group group_id="O2">
            <title>Control, IUD Insertion Group</title>
            <description>If the subject is assigned to the control group (sterile, surgical lubricant jelly):
•She will be given a pre-filled vaginal inserter with 10 ml of surgical lubricant jelly and will be asked to insert it vaginally 20-30 minutes prior to the start of her procedure. The subject will not know if she received the active drug or a placebo.
Surgical Lubricant Jelly: Patient-administered vaginal surgical lubricant jelly verse Lidocaine jelly</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline Pain as Measured by a Visual Analog Scale</title>
          <description>Pain as measured by a Visual Analog Scale (VAS). This scale is 0-100--on the scale &quot;0&quot; had &quot;no pain&quot; and &quot;100&quot; had &quot;worst pain imaginable&quot; as anchors. A higher score indicates higher pain.</description>
          <population>Per protocol analysis</population>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="0" upper_limit="77"/>
                    <measurement group_id="O2" value="2" lower_limit="0" upper_limit="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain After Speculum Placement as Measured by a Visual Analog Scale</title>
        <description>Pain as measured by a Visual Analog Scale (VAS). This scale is 0-100--on the scale &quot;0&quot; had &quot;no pain&quot; and &quot;100&quot; had &quot;worst pain imaginable&quot; as anchors. A higher score indicates higher pain.</description>
        <time_frame>Intraoperative</time_frame>
        <population>Per protocol analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Experimental, IUD Insertion Group</title>
            <description>If the subject is assigned to the experimental group (vaginal lidocaine jelly):
She will be given a pre-filled vaginal inserter with 10 ml of 2% lidocaine jelly) and will be asked to insert it vaginally 20-30 minutes prior to the start of her procedure. The subject will not know if she received the active drug or a placebo.
Vaginal 2% Lidocaine: Patient-administered vaginal Lidocaine jelly verse surgical lubricant jelly</description>
          </group>
          <group group_id="O2">
            <title>Control, IUD Insertion Group</title>
            <description>If the subject is assigned to the control group (sterile, surgical lubricant jelly):
•She will be given a pre-filled vaginal inserter with 10 ml of surgical lubricant jelly and will be asked to insert it vaginally 20-30 minutes prior to the start of her procedure. The subject will not know if she received the active drug or a placebo.
Surgical Lubricant Jelly: Patient-administered vaginal surgical lubricant jelly verse Lidocaine jelly</description>
          </group>
        </group_list>
        <measure>
          <title>Pain After Speculum Placement as Measured by a Visual Analog Scale</title>
          <description>Pain as measured by a Visual Analog Scale (VAS). This scale is 0-100--on the scale &quot;0&quot; had &quot;no pain&quot; and &quot;100&quot; had &quot;worst pain imaginable&quot; as anchors. A higher score indicates higher pain.</description>
          <population>Per protocol analysis</population>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7" lower_limit="0" upper_limit="81"/>
                    <measurement group_id="O2" value="11" lower_limit="0" upper_limit="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain After Tenaculum Placement as Measured by a Visual Analog Scale</title>
        <description>Pain as measured by a Visual Analog Scale (VAS). This scale is 0-100--on the scale &quot;0&quot; had &quot;no pain&quot; and &quot;100&quot; had &quot;worst pain imaginable&quot; as anchors. A higher score indicates higher pain.</description>
        <time_frame>Intraoperative</time_frame>
        <population>Per protocol analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Experimental, IUD Insertion Group</title>
            <description>If the subject is assigned to the experimental group (vaginal lidocaine jelly):
She will be given a pre-filled vaginal inserter with 10 ml of 2% lidocaine jelly) and will be asked to insert it vaginally 20-30 minutes prior to the start of her procedure. The subject will not know if she received the active drug or a placebo.
Vaginal 2% Lidocaine: Patient-administered vaginal Lidocaine jelly verse surgical lubricant jelly</description>
          </group>
          <group group_id="O2">
            <title>Control, IUD Insertion Group</title>
            <description>If the subject is assigned to the control group (sterile, surgical lubricant jelly):
•She will be given a pre-filled vaginal inserter with 10 ml of surgical lubricant jelly and will be asked to insert it vaginally 20-30 minutes prior to the start of her procedure. The subject will not know if she received the active drug or a placebo.
Surgical Lubricant Jelly: Patient-administered vaginal surgical lubricant jelly verse Lidocaine jelly</description>
          </group>
        </group_list>
        <measure>
          <title>Pain After Tenaculum Placement as Measured by a Visual Analog Scale</title>
          <description>Pain as measured by a Visual Analog Scale (VAS). This scale is 0-100--on the scale &quot;0&quot; had &quot;no pain&quot; and &quot;100&quot; had &quot;worst pain imaginable&quot; as anchors. A higher score indicates higher pain.</description>
          <population>Per protocol analysis</population>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30" lower_limit="0" upper_limit="86"/>
                    <measurement group_id="O2" value="38" lower_limit="0" upper_limit="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data for each subject was assessed from time of consent to time of appointment discharge. On average this was 90 minutes.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Experimental, IUD Insertion Group</title>
          <description>If the subject is assigned to the experimental group (vaginal lidocaine jelly):
She will be given a pre-filled vaginal inserter with 10 ml of 2% lidocaine jelly) and will be asked to insert it vaginally 20-30 minutes prior to the start of her procedure. The subject will not know if she received the active drug or a placebo.
Vaginal 2% Lidocaine: Patient-administered vaginal Lidocaine jelly verse surgical lubricant jelly</description>
        </group>
        <group group_id="E2">
          <title>Control, IUD Insertion Group</title>
          <description>If the subject is assigned to the control group (sterile, surgical lubricant jelly):
•She will be given a pre-filled vaginal inserter with 10 ml of surgical lubricant jelly and will be asked to insert it vaginally 20-30 minutes prior to the start of her procedure. The subject will not know if she received the active drug or a placebo.
Surgical Lubricant Jelly: Patient-administered vaginal surgical lubricant jelly verse Lidocaine jelly</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Research Manager</name_or_title>
      <organization>Stanford University, Department of OB/GYN</organization>
      <phone>6507211562</phone>
      <email>familyplanningresearch@stanford.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

